Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
ApexOnco Front Page
Recent articles
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
The group’s $8bn acquisition of Merus was the standout in the third quarter.
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
Key FDA decisions are expected to face delays.
After trimming its cell therapy pipeline last year, the group is now out entirely.
The Titan CD8-guiding technology seems to have spawned a new variant.
